This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Acer (ACER) to Get Acquired by Zevra for $91M, Stock Up
by Zacks Equity Research
Acer (ACER) surges as Zevra Therapeutics offers to acquire it for approximately $91 million.
Acer Therapeutics Inc. (ACER) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Acer Therapeutics Inc. (ACER) closed at $0.76 in the latest trading session, marking a +1.13% move from the prior day.
ACER's Stock Down on Failure of Phase II Study, Cash Updates
by Zacks Equity Research
ACER announces the failure of its phase IIa study of ACER-801 to treat vasomotor symptoms associated with menopause, along with its extinguishing cash runway. Stock down.
Acer Therapeutics Inc. (ACER) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Acer Therapeutics Inc. (ACER) closed the most recent trading day at $1.67, moving -1.76% from the previous trading session.
Acer Therapeutics Inc. (ACER) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Acer Therapeutics Inc. (ACER) closed at $2.16, marking a -0.92% move from the previous day.
Acer Therapeutics Inc. (ACER) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Acer Therapeutics Inc. (ACER) closed at $2.18, marking a +1.87% move from the previous day.
Acer Therapeutics Inc. (ACER) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Acer Therapeutics Inc. (ACER) closed the most recent trading day at $2.09, moving -0.48% from the previous trading session.
Acer (ACER) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Acer Therapeutics' (ACER) fourth-quarter earnings call, investors' focus is likely to be on the company's pipeline development.
Acer Therapeutics Inc. (ACER) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Acer Therapeutics Inc. (ACER) closed at $2.28 in the latest trading session, marking a -1.72% move from the prior day.
Acer Therapeutics Inc. (ACER) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Acer Therapeutics Inc. (ACER) closed at $2.40, marking a +1.27% move from the previous day.
Acer Therapeutics Inc. (ACER) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Acer Therapeutics Inc. (ACER) closed at $2.39 in the latest trading session, marking a -0.83% move from the prior day.
Zacks Industry Outlook Highlights Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings and Acer Therapeutics
by Zacks Equity Research
Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings and Acer Therapeutics are part of the Zacks Industry Outlook article.
5 Stocks to Buy as the Drug Industry Bets Big on Innovation
by Kinjel Shah
Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. DYN, SLN, TCRT, ASRT and ACER may prove to be good additions to one's portfolio.
Are Medical Stocks Lagging Acer Therapeutics (ACER) This Year?
by Zacks Equity Research
Here is how Acer Therapeutics Inc. (ACER) and Syndax Pharmaceuticals (SNDX) have performed compared to their sector so far this year.
Acer Therapeutics Inc. (ACER) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Acer Therapeutics Inc. (ACER) closed the most recent trading day at $2.76, moving -0.36% from the previous trading session.
Biotech Stock Roundup: GILD's HIV Drug Approval, PRQR Surges on LLY Deal & More
by Zacks Equity Research
Updates from Gilead Sciences (GILD) and ProQR (PRQR) are the key highlights from the biotech sector during the past week.
PDS Biotech (PDSB) Up on Data From HPV-Positive Cancer Study
by Zacks Equity Research
A mid-stage study data shows that treatment with PDS Biotech's (PDSB) lead candidate in advanced HPV-positive cancer patients achieved a median overall survival of 21 months.
Minerva (NERV) Down; FDA Denies Review Schizophrenia Drug NDA
by Zacks Equity Research
Minerva (NERV) confirmed that the FDA's refuse-to-file letter on its regulatory filing, seeking approval for roluperidone, to treat symptoms of schizophrenia remains in effect.
Are Medical Stocks Lagging Acer Therapeutics (ACER) This Year?
by Zacks Equity Research
Here is how Acer Therapeutics Inc. (ACER) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Acer Therapeutics Inc. (ACER) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Acer Therapeutics Inc. (ACER) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
ACER Down Despite FDA Nod for Urea Cycle Disorders Drug
by Zacks Equity Research
The FDA approves Acer Therapeutics' (ACER) Olpruva (sodium phenylbutyrate) to treat certain patients with urea cycle disorders. Share price falls 33.3% following the announcement.
Is Acer Therapeutics (ACER) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Acer Therapeutics Inc. (ACER) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Talaris (TALS) Down on Patient Death From Renal Transplant Study
by Zacks Equity Research
Talaris Therapeutics (TALS) reports a patient death from its late-stage study evaluating its experimental drug, FCR001, in living donor kidney transplant patients. Stock down.
RedHill Biopharma (RDHL) Up on New Patent for COVID-19 Candidate
by Zacks Equity Research
RedHill Biopharma (RDHL) receives a new patent from the United States Patent and Trademark Office for its investigational COVID-19 candidate, opaganib, in COVID-19 patients with pneumonia. Stock up.
Catalyst Pharmaceuticals (CPRX) Rallies 80.69% YTD: Here's Why
by Zacks Equity Research
Catalyst (CPRX) price rallies on FDA approval of the sNDA of its lead drug, Firdapse, approved to treat LEMS in patients above six years of age.